Literature DB >> 29030784

Anti-TNF-α antibody alleviates insulin resistance in rats with sepsis-induced stress hyperglycemia.

W Qu1, C Han1, M Li1, J Zhang2, Z Jiang3.   

Abstract

PURPOSE: To explore the effects and mechanisms of anti-tumor necrosis factor-α (TNF-α) antibody on insulin resistance (IR) in rats with sepsis-induced stress hyperglycemia.
METHODS: The sepsis-induced stress hyperglycemic rat model was constructed by cecal ligation and puncture combined with the intraperitoneal injection of lipopolysaccharide. The rats were randomly divided into six groups: normal control (NC) group, surgical rats (Cntl) group, high-dose anti-TNF-α antibody therapy (TNF, 6 mg/kg) group, low-dose anti-TNF-α antibody therapy (Tnf, 3 mg/kg) group, insulin therapy (INS) group, and INS + Tnf group. The blood glucose and serum insulin concentrations were detected, followed by analysis of intraperitoneal glucose tolerance test (IPGTT) and hyperinsulinemic-euglycemic clamp. Finally, the expression levels of phospho-Akt (p-Akt), Akt, p-mTOR, mTOR, nuclear factor-κB (NFκB), I kappa beta kinase (IKKβ), and suppressor of cytokine signaling (SOCS-3) were detected by western blotting.
RESULTS: There was no significant difference in blood glucose concentrations among these groups, while the serum insulin concentration in TNF and Tnf groups was lower than that in the Cntl group at postoperative 6 h (P < 0.05). IPGTT analysis revealed that blood glucose level was lower in the TNF group than that in the Cntl group (P < 0.05). The glucose infusion rate in the Cntl group was lower than that in the Tnf and TNF groups (P < 0.05). The p-Akt/Akt, p-mTOR/mTOR ratio, and expression levels of NFκB, IKKβ and SOCS-3 were lower in the drug intervention than that in the Cntl group (P < 0.05).
CONCLUSIONS: Anti-TNF-α antibody could reduce IR by inhibiting AKt/mTOR signaling pathway and the expression levels of NFκB, IKKβ, and SOCS-3 in rats with sepsis-induced stress hyperglycemia.

Entities:  

Keywords:  Anti-TNF-α antibody; Insulin sensitivity; Stress hyperglycemia

Mesh:

Substances:

Year:  2017        PMID: 29030784     DOI: 10.1007/s40618-017-0742-7

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  35 in total

Review 1.  Tumor necrosis factor inhibitors for inflammatory bowel disease.

Authors:  Ole Haagen Nielsen; Mark Andrew Ainsworth
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

2.  Akt mediates insulin induction of glucose uptake and up-regulation of GLUT4 gene expression in brown adipocytes.

Authors:  R Hernandez; T Teruel; M Lorenzo
Journal:  FEBS Lett       Date:  2001-04-13       Impact factor: 4.124

Review 3.  Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes.

Authors:  Joseph L Evans; Ira D Goldfine; Betty A Maddux; Gerold M Grodsky
Journal:  Endocr Rev       Date:  2002-10       Impact factor: 19.871

4.  Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats.

Authors:  Núria Lloberas; Josep M Cruzado; Marcella Franquesa; Immaculada Herrero-Fresneda; Joan Torras; Gabriela Alperovich; Inés Rama; August Vidal; Josep M Grinyó
Journal:  J Am Soc Nephrol       Date:  2006-04-05       Impact factor: 10.121

5.  SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-alpha in the adipose tissue of obese mice.

Authors:  B Emanuelli; P Peraldi; C Filloux; C Chavey; K Freidinger; D J Hilton; G S Hotamisligil; E Van Obberghen
Journal:  J Biol Chem       Date:  2001-10-16       Impact factor: 5.157

Review 6.  Inflammatory status and insulin resistance.

Authors:  Robert F Grimble
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2002-09       Impact factor: 4.294

Review 7.  Stress-hyperglycemia, insulin and immunomodulation in sepsis.

Authors:  Paul E Marik; Murugan Raghavan
Journal:  Intensive Care Med       Date:  2004-02-26       Impact factor: 17.440

Review 8.  Inflammatory pathways and insulin action.

Authors:  G S Hotamisligil
Journal:  Int J Obes Relat Metab Disord       Date:  2003-12

Review 9.  Bench-to-bedside review: Glucose and stress conditions in the intensive care unit.

Authors:  Marie-Reine Losser; Charles Damoisel; Didier Payen
Journal:  Crit Care       Date:  2010-08-20       Impact factor: 9.097

Review 10.  Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF.

Authors:  Roman Fischer; Olaf Maier
Journal:  Oxid Med Cell Longev       Date:  2015-03-05       Impact factor: 6.543

View more
  5 in total

1.  Protective effect of anisodamine hydrobromide on lipopolysaccharide-induced acute kidney injury.

Authors:  Feng Wan; Xiaoqiang Du; Huan Liu; Xueling He; Ye Zeng
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

2.  Effect of pioglitazone on skeletal muscle lipid deposition in the insulin resistance rat model induced by high fructose diet under AMPK signaling pathway.

Authors:  Lixin Tan; An Song; Luping Ren; Chao Wang; Guangyao Song
Journal:  Saudi J Biol Sci       Date:  2020-03-18       Impact factor: 4.219

3.  Association of the systemic host immune response with acute hyperglycemia in mechanically ventilated septic patients.

Authors:  Nauman Farooq; Byron Chuan; Hussain Mahmud; Samar R El Khoudary; Seyed Mehdi Nouraie; John Evankovich; Libing Yang; Daniel Dunlap; William Bain; Georgios Kitsios; Yingze Zhang; Christopher P O'Donnell; Bryan J McVerry; Faraaz Ali Shah
Journal:  PLoS One       Date:  2021-03-23       Impact factor: 3.240

4.  MiR-539-5p inhibits the inflammatory injury in septic H9c2 cells by regulating IRAK3.

Authors:  Xiaochen Hu; Hongjun Miao
Journal:  Mol Biol Rep       Date:  2021-11-10       Impact factor: 2.316

5.  Atorvastatin and diacerein reduce insulin resistance and increase disease tolerance in rats with sepsis.

Authors:  K L C da Silva; A P Camacho; F C Mittestainer; B M Carvalho; A Santos; D Guadagnini; A G Oliveira; M J A Saad
Journal:  J Inflamm (Lond)       Date:  2018-05-09       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.